Novo Nordisk: trial failure and impact on results

(CercleFinance.com) - Novo Nordisk yesterday announced that a Phase III trial evaluating ocedurenone in patients with uncontrolled hypertension and advanced chronic kidney disease had failed to meet its primary endpoint.


Indeed, after an interim analysis, an independent monitoring committee concluded that the trial did not meet pre-established futility criteria, leading Novo Nordisk to discontinue the trial.

As a result, Novo Nordisk will record an impairment loss of around 5.7bn DKK in Q2 2024.

This is expected to have a negative impact on operating profit growth in 2024. The company will publish its financial results for the first six months of 2024 and FY outlook on 7 August 2024.


Copyright (c) 2024 CercleFinance.com. All rights reserved.